Author:
Bothou Christina,Beuschlein Felix,Nowak Albina
Abstract
Abstract
Context
Fabry Disease (FD) is a rare X-linked storage disease characterised by a-galactosidase A deficiency and diffuse organ accumulation of glycosphingolipids. Enzyme replacement and chaperone therapies are only partially effective. It remains unclear if FD-related endocrine disorders contribute to the observed morbidity.
Objective
To investigate the function of the endocrine system in patients with FD.
Design
We conducted an observational prospective study from 2017 to 2020.
Setting and patients
We included 77 patients with genetically confirmed FD (27 men, 20/27 Classic, 7/26 Late Onset phenotype, 50 women, 41/50 and 9/50 respectively), who are systematically followed by our reference centre.
Results
36/77 (46.8%) patients had VitD deficiency (25(0H)VitD <20 μg/L) despite the fact that 19/36 (52.8%) were substituted with cholecalciferol. Only 21/77 (27.3%) patients had normal VitD levels without VitD substitution. 11/77 (14.3%) had significant hypophosphatemia (p < 0.80 mmol/L). Three new cases (3.9%) of subclinical, two (2.6%) of overt and six (7.8%) of known hypothyroidism were identified. Of note, men had significantly higher renin levels than women [61.4 (26.1–219.6) vs.25.4 (10.9–48.0) mU/L, p = 0.003]. There were no major abnormalities in adrenal, growth and sex-hormone axes. Patients of Classic phenotype had significantly higher High-Density Lipoprotein Cholesterol (HDL-C) levels (p = 0.002) and in men those levels were positively correlated with globotriaosylsphingosin (Lyso-Gb3) values. 10/77 (13%) of the patients were underweight.
Conclusions
VitD supplementation should be considered for all patients with FD. Thyroid screening should be routinely performed. Malnutrition should be prevented or treated, particularly in Classic phenotype patients. Overall, our data suggest that FD specialists should actively seek and diagnose endocrine disorders in their patients.
Funder
an received lecturing honoraria and research support from sanofi genzyme, takeda and amicus.
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism
Reference51 articles.
1. Y.A. Zarate, R.J. Hopkin, Fabry’s disease. Lancet 372, 1427–1435 (2008)
2. R.J. Desnick, R. Brady, J. Barranger et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann. Intern. Med. 138, 338–346 (2003)
3. M. Arends, C. Wanner, D. Hughes et al. Characterization of classical and nonclassical Fabry disease: a multicenter study. J. Am. Soc. Nephrol. 28, 1631–1641 (2017)
4. Deegan P.B., Bahner F., Barba M., Hughes D.A., Beck M. Fabry disease in females: clinical characteristics and effects of enzyme replacement therapy. In: Mehta A., Beck M., Sunder-Plassmann G., eds. Fabry Disease: Perspectives from 5 Years of FOS. Oxford, 2006.
5. E.H. McCafferty, L.J. Scott, Migalastat: a review in Fabry disease. Drugs 79, 543–554 (2019)
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献